Literature DB >> 8308840

The use of acyclovir in suspected encephalitis.

J Gleadle1, C Dixon, M M Brown, F Schon.   

Abstract

The early use of intravenous acyclovir in herpes simplex encephalitis (HSE) is essential. However, rapid diagnostic tests are not freely available. Hence, all patients with suspected encephalitis may need to be commenced on acyclovir. In our study, of 34 patients with suspected encephalitis, only two eventually had HSE confirmed, 19 had encephalitis not due to herpes simplex and in 13 a non-encephalitis illness was finally diagnosed. Guidelines for the use of acyclovir in suspected encephalitis are given aimed at minimizing the drug cost whilst still protecting all cases of presumed HSE.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8308840      PMCID: PMC1294270          DOI: 10.1177/014107689408700105

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   18.000


  5 in total

Review 1.  Herpes simplex encephalitis in a patient with lymphoma. Relapse following acyclovir therapy.

Authors:  A L Rothman; S H Cheeseman; S N Lehrman; A Cederbaum; R H Glew
Journal:  JAMA       Date:  1988-02-19       Impact factor: 56.272

2.  Early diagnosis of herpes simplex encephalitis by MRI.

Authors:  G Schroth; J Gawehn; A Thron; A Vallbracht; K Voigt
Journal:  Neurology       Date:  1987-02       Impact factor: 9.910

3.  Rapid diagnosis of herpes simplex encephalitis by nested polymerase chain reaction assay of cerebrospinal fluid.

Authors:  E Aurelius; B Johansson; B Sköldenberg; A Staland; M Forsgren
Journal:  Lancet       Date:  1991-01-26       Impact factor: 79.321

4.  Vidarabine versus acyclovir therapy in herpes simplex encephalitis.

Authors:  R J Whitley; C A Alford; M S Hirsch; R T Schooley; J P Luby; F Y Aoki; D Hanley; A J Nahmias; S J Soong
Journal:  N Engl J Med       Date:  1986-01-16       Impact factor: 91.245

5.  Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients.

Authors:  B Sköldenberg; M Forsgren; K Alestig; T Bergström; L Burman; E Dahlqvist; A Forkman; A Frydén; K Lövgren; K Norlin
Journal:  Lancet       Date:  1984-09-29       Impact factor: 79.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.